Loading clinical trials...
Loading clinical trials...
A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors
Conditions
Interventions
GQ1001
Locations
24
United States
M.D. Anderson Cancer Center
Houston, Texas, United States
Scientia Clinical Research Limited
Randwick, New South Wales, Australia
Cabrini Institute in Melbourne, Australia
Melbourne, Victoria, Australia
The first affiliated hospital of Bengbu medical college
Bengbu, Anhui, China
Beijing Tongren Hospital Affiliated to Capital University of Medical Sciences
Beijing, Beijing Municipality, China
Chinese PLA general hospital
Beijing, Beijing Municipality, China
Start Date
July 7, 2020
Primary Completion Date
March 1, 2024
Completion Date
May 1, 2024
Last Updated
December 5, 2023
NCT06253871
NCT04585750
NCT04886531
NCT07459673
NCT07102381
NCT07053085
Lead Sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions